Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mepyramine→

Mepyramine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
91-84-9
Molecular formula
C17H23N3O
Molecular weight
285.391 g/mol
Drug class
First-generation alkylamine antihistaminehistamine H1 receptor antagonist
Mechanism of action
Competitively antagonises peripheral H1 histamine receptors, reducing histamine-mediated vasodilation, vascular permeability, itching and allergic symptoms. It can also produce sedative and anticholinergic effects.
Indications / reported uses
  • Symptomatic relief of allergic rhinitis, urticaria, pruritus and allergic conjunctivitis in countries where mepyramine products are authorised; topical formulations have separate local-use indications

Sources: NLM MeSH — Mepyramine (pyrilamine) · PubMed — Mepyramine antihistamine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mepyramine Environmental Risk Assessment (ERA) (the Mepyramine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.